Download App

Log in to access Online Inquiry
Company Overview More
The company is approved by Henan Economic system Reform Commission (1998) No. 38, with Zhengzhou Zhongsheng Industrial Group Co., Ltd. as the main sponsor. Henan Zhiyi Investment and Development Co., Ltd., Zhengzhou Zhulin Xianzhu washing products Co., Ltd., Zhengzhou Zhulin Refractory Co., Ltd., Gongyi Zhulin Xinhua Packaging material Factory and other five enterprises jointly initiated and established the joint stock co., Ltd. With the approval of document No. 98 issued by CSRC [1999], the company issued 35 million public shares on August 13, 1999, with a total share capital of 136.14524 million yuan. The company's main business is drug manufacturing and drug R & D services, including pharmaceutical preparations, traditional Chinese medicine slices, drug R & D services and the circulation of pharmaceutical materials. The main products of the company's pharmaceutical preparation business include Shuanghuanglian oral liquid series, Shuanghuanglian mixture, children's compound chicken gold chewable tablets, Huperzine A tablets and so on. Among them, Shuanghuanglian oral liquid (concentrated), Shuanghuanglian oral liquid (children's type), Shuanghuanglian mixture and children's compound chicken inner gold chewing tablets are the company's exclusive products. The main products of traditional Chinese medicine business include bran fried Atractylodes macrocephala, Nanxing, Radix Pseudostellariae, fried Coix seed, fried gardenia and other common slices, as well as special fine slices such as Ganoderma lucidum, wild ginseng, Dendrobium, Polygonum multiflorum, Monascus, Baiyao decoction, Liushen qu and so on. Enterprise honor: the all-China Federation of Industry and Commerce Pharmaceutical Chamber of Commerce awarded the company the honor of "Anti-epidemic Charity and Love", Henan High-tech Enterprises, "National High-tech industrialization demonstration Project", "excellent Enterprises in Zhengzhou" and so on.
CEO: --
Market: --
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

600222 Henan Taloph Pharmaceutical Stock
5.630-0.010-0.18%
YOY
Do not show
Hide blank lines
(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30(Q6)2021/06/30
Assets
Current assets
Money funds
-46.44% 264.43M -21.91% 380.55M 23.28% 571.22M -3.84% 380.4M
Transactional financial assets
26.77% 211.8M 37.7% 285.67M 26.96% 203.95M 6.17% 171.4M
Notes receivable and accounts receivable
3.58% 689.34M -0.38% 587.51M -9.11% 598.44M 22.98% 687.85M
-Notes receivable
-58.01% 53.12M -34.43% 66.73M -81.48% 18.51M 163.05% 102.18M
-Accounts receivable
18.04% 636.22M 6.72% 520.77M 3.84% 579.93M 12.52% 585.67M
Other receivables (including interest and dividends)
-4.65% 86.57M -28.44% 56.05M -40.19% 88.82M -45.02% 77.38M
-Other receivable
-- -- -- -- -- -- -44.62% 77.38M
Contractual assets
56.59% 160.83M 58.02% 157.2M 60.1% 130.05M 34.47% 100.5M
Advance payment
94.1% 117.34M 36.13% 87.59M 69.24% 106.24M -11.11% 62.8M
Inventories
21.23% 424.79M 9.68% 381.85M 42.78% 404.57M 15.8% 345.3M
Non-current assets due within one year
-- -- -- -- -- 28.84K -- 43.99K
Other current assets
7.83% 7.12M 23.87% 7.29M -32.45% 5.27M -34.93% 3.98M
Total current assets
1.29% 1.96B 3.35% 1.94B 12.99% 2.11B 7.2% 1.83B
Non Current assets
Other equity investment
2.25% 799.21M 58.02% 805.4M -- 703.95M -- 809.31M
Other non-current financial assets
-0.64% 4.42M 1.62% 4.5M -89.93% 4.48M -1.11% 4.47M
Long-term equity investment
-22.16% 15.47M -19.91% 15.72M -77.95% 40.68M -86.28% 19.65M
Fixed assets
-- -- -- -- -- -- 3.59% 460.3M
Fixed assets liquidation
-- -- -- -- -- -- -- 0
Constru in process
-- -- -- -- -- -- -11.67% 24.18M
Construction materials
-- -- -- -- -- -- -- 0
Intangible assets
-8.12% 51.8M -7.73% 53.1M -7.72% 53.95M -7.66% 55.11M
Development expenditure
4.78% 20.32M 2.19% 19.74M 2.04% 19.68M 1.67% 19.57M
Goodwill
0% 286.49M 0% 286.49M 0% 286.49M 0% 286.49M
Long deferred expense
13.16% 15.36M 17.56% 16.06M 23.74% 14.97M 20.46% 14.5M
Deferred tax assets
24.92% 53.11M 11.11% 52.4M 24.27% 46.16M 30.11% 45.52M
Usufruct assets
-20.28% 33.29M -22.03% 36.62M -- 38.58M -- 41.57M
Other non current assets
0% 45.52M -14.43% 47.05M 0% 45.52M 0% 45.52M
Total non current assets
1.4% 1.83B 18.41% 1.84B 51.06% 1.75B 69.49% 1.83B
Total assets
1.34% 3.79B 10.16% 3.78B 27.57% 3.86B 31.31% 3.66B
Liabilities
Current liabilities
Short term loan
29.78% 974.05M 29.77% 973.58M 94.87% 1.09B 56.2% 962M
Notes payable and accounts payable
105.19% 437.55M 67.99% 355.65M 63.18% 355.83M 30.5% 246.22M
-Notes payable
1548% 164.8M 900% 100M 130.77% 150M -4.61% 60M
-Accounts payable
34.2% 272.75M 26.74% 255.65M 34.48% 205.83M 48.07% 186.22M
Contract liabilities
-4.13% 43.29M -19.25% 49.47M -38.63% 36.48M 11.8% 52.42M
Salaries payable
51.49% 7.1M 13.06% 9.69M 86.99% 12.87M -35.03% 5.53M
Taxs payable
-3.02% 12.96M 11.07% 18.16M 72.34% 18.48M 74.03% 16.96M
Other payable (including interest and dividends)
71.98% 80.44M 71.65% 80.04M 998% 112.13M 227.73% 38.85M
-Interest payable
-- -- -- -- -- -- -- 0
-Dividend payable
-- -- -- -- -- -- -- 9.01M
-Other payable
-- -- -- -- -- -- 151.74% 29.84M
Non current liabilities due within one year
-72.44% 111.97M -62% 158.74M -- 165.22M -- 159.19M
Other current liabilities
2.37% 3.29M 48.36% 4.35M 33.39% 2.66M 50.76% 2.89M
Total current liabilities
12.64% 1.67B 8.86% 1.65B 103.49% 1.79B 64.6% 1.48B
Current liabilities
Long term loan
-84.6% 20.37M -85.06% 20.37M -96.21% 20.37M -96.23% 20.42M
Long term account payable
-- -- -- -- -- -- -- 35.54M
Specific account payable
-- -- -- -- -- -- -- 0
Estimate liabilities
-- 1.62M -- 1.62M -- -- -- --
Deferred tax liabilities
7.55% 130.47M 132.45% 132.42M 4862.56% 106.92M 8105.02% 135.95M
Lease liabilities
-50.53% 20.5M -30.34% 23.55M -- 39.58M -- 41.21M
Other non current liabilities
-- -- 0% 130M 0% 130M -- 130M
Total non current liabilities
-52.78% 213.72M -8.31% 356.46M -52.77% 339.71M -33.11% 363.11M
Exceptional items of total current liabilities
-- 0 -- 0 -- 0 -- 0
Total liabilities
-2.66% 1.88B 5.36% 2.01B 33.29% 2.13B 27.88% 1.85B
Shareholders equity
Paid-in capital
0% 573.89M 0% 573.89M 0% 573.89M 0% 573.89M
Capital reserve funds
14.81% 675.23M 0% 588.14M -9.9% 588.14M -9.9% 588.14M
Surplus reserve funds
0% 50.91M 0% 50.91M 0% 50.91M 0% 50.91M
Retained profit
-13.05% 183.57M -1.64% 181.24M 9.17% 203.54M 9.34% 202.43M
Less:Treasury stock
0% 48.7M -50.54% 48.7M -61.13% 48.7M -61.13% 48.7M
Other composite income
-0.43% 311.31M 103.65% 315.04M 209.52% 253.86M -- 323M
Shareholders equity without minority interests
3.45% 1.75B 14.25% 1.66B 14.14% 1.62B 26.34% 1.69B
Minority interests
37.72% 158.97M 51.81% 117.13M 4319.17% 102.17M 5066.99% 119.01M
Total shareholder equity
5.64% 1.91B 16.14% 1.78B 21.13% 1.72B 35% 1.81B
Total liabilityies and equity
1.34% 3.79B 10.16% 3.78B 27.57% 3.86B 31.31% 3.66B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
--Unqualified opinion----
Auditor
--Beijing Xinghua Accounting firm (Special General Partnership)----

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%